Samsung Biologics breaks ground on 'super plant'

By The Science Advisory Board staff writers

Samsung Biologics broke ground on the construction of its biopharma manufacturing facility Plant 4 in Incheon, South Korea during a virtual ceremony.

It has been dubbed the "super plant" because the new, multistory 238,000-sq-mt facility will boast 256,000 L of total manufacturing capacity. Once completed, it will be the largest biopharmaceutical manufacturing facility in the world, according to the company.

Samsung Biologics Plant 4 Groundbreaking Ceremony. Image courtesy of Samsung Biologics.
Samsung Biologics Plant 4 groundbreaking ceremony. Image courtesy of Samsung Biologics.

With this plant, Samsung Biologics anticipates being responsible for a third of the total global bio-contract manufacturing organization capacity, offering a combined sum of 620,000 L from a single site. Plant 4 will feature a modular design, allowing for certain parts of the facility to begin manufacturing by the end of 2022. The plant is expected to be fully operational in 2023.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?